Jichuan Pharmaceutical and Zedman Pharmaceuticals reach a commercial partnership

Recently, Jichuan Pharmaceutical announced the official signing of a cooperation agreement with Zedman Pharmaceuticals. Jichuan Pharmaceutical will obtain the exclusive commercialization rights of Zelmei Benwimod cream in the People's Republic of China. As the world's first approved aromatic hydrocarbon receptor modulator for the treatment of atopic dermatitis in children aged 2 and above as well as adults, Zelmei fills the gap in non-hormonal topical treatment for eczema in young children globally.